Janssen Biotech goes to court to block launch of Remicade biosimilar

Jansen Biotech is not going to let a second biosimilar version of its blockbuster rheumatoid arthritis drug Remicade hit pharmacy shelves in the United States without a fight. The Horsham, Pa.-based subsidiary of Johnson& Johnson (NYSE: JNJ) has filed a patent infringement lawsuit with U.S. District Court in New Jersey to prevent Samsung Bioepis Co. Ltd. of South Korea from introducing Renflexis later this year. Biosimilar products are different from generic drugs, which are chemically identical…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news